Diagnostic utility of 11 C‐methionine PET/CT in primary hyperparathyroidism in a UK cohort: A single‐centre experience and literature review
Authors' conclusion
This study highlights a diagnostic role for 11C-methionine PET/CT in patients that have undergone unsuccessful prior surgery or have equivocal or negative prior imaging results, aiding localization and a targeted surgical approach.
Study context
- Population
- Patients with primary hyperparathyroidism (PHPT) who underwent 11C-methionine PET/CT 2014–2022 at Addenbrooke's Hospital (Cambridge, UK)
- Participants
- 45 patients
- Outcome
- Diagnostic utility of 11C-methionine PET/CT vs histopathological and biochemical outcomes after surgery
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Detection of parathyroid adenomas
| Group | Sensitivity |
|---|---|
| 11C-methionine PET/CT | 70.0% (95% CI 55.8 - 84.2%) |
11C-methionine PET/CT
Sensitivity70.0% (95% CI 55.8 - 84.2%)
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Persistent PHPT after previous surgery: candidate lesion identified | 11C-methionine PET/CT 60.0% |
| Adenoma correctly identified when not localised on other imaging | 11C-methionine PET/CT 75.0% |
- Persistent PHPT after previous surgery: candidate lesion identified — Histologically confirmed
- 5 (50.0%)
- Persistent PHPT after previous surgery: candidate lesion identified: 6 of 10 patients
- Adenoma correctly identified when not localised on other imaging: 9 out of 12 patients
Original publication
Diagnostic utility of 11 C‐methionine PET/CT in primary hyperparathyroidism in a UK cohort: A single‐centre experience and literature review. Clin Endocrinol (Oxf). Published 5 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →